Product Name :
DLC1 polyclonal antibody Background :
Many tumor supressor genes are thought to reside on chromosome 3p because one copy of this region is frequently found to be deleted in several carcinomas. The gene encoding DLEC1 (deleted in lung and esophageal cancer protein 1), a 1,755 amino acid cytoplasmic protein, is located within a chromosomal region that is subject to abberations in many cancer cell lines and primary cancers. Reduced invasiveness and suppression of cell growth occurs when DLEC1 cDNA is introduced into a variety of cancer cell lines, suggesting that defects in the transcription of DLEC1 is a cause of lung, esophageal, and renal cancers. Evidence also suggests that methylation of the DLEC1 promoter may be associated with a poor prognosis in non-small cell lung carcinoma and nasopharyngeal carcinoma. With highest expression in kidney and prostate, there are three isoforms of DLEC1 that exist as a result of alternative splicing events. Product :
Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
Recognizes endogenous levels of DLC1 protein. Immunogen :
KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human DLC1. The exact sequence is proprietary. Conjugate :
Unconjugated Modification :
Unmodification

• 
  Western blot analysis of DLC1 expression in A549 (A), Hela (B), rat oviduct (C), BV2 (D) whole cell lysates.
• 
  Immunohistochemical analysis of DLC1 staining in human prostate cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
• 
  Immunohistochemical analysis of DLC1 staining in human prostate cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.

---

Price/Size :

USD 368/1mg/vial

---

---

Tips: 

For phospho antibody, we provide phospho peptide（0.5mg) and non-phospho peptide(0.5mg).

---

Describe :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.

---

Formula:

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.

---

Storage:

The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C. 

---

Note :

This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.

---